Clinical efficacy of OS-01 peptide formulation in reducing the signs of periorbital skin aging.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Clinical efficacy of OS-01 peptide formulation in reducing the signs of periorbital skin aging.
- Published In:
- International journal of cosmetic science, 47(3), 455-465 (2025)
- Authors:
- Zonari, Alessandra, Brace, Lear E, Li, Fanghua, Harder, Nathaniel H O, Harker, Claire, Jacob, Carolyn, Kaufman, Joely, Chilukuri, Suneel, Oliveira, Carolina R, Boroni, Mariana, Carvalho, Juliana L
- Database ID:
- RPEP-14666
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-14666APA
Zonari, Alessandra; Brace, Lear E; Li, Fanghua; Harder, Nathaniel H O; Harker, Claire; Jacob, Carolyn; Kaufman, Joely; Chilukuri, Suneel; Oliveira, Carolina R; Boroni, Mariana; Carvalho, Juliana L. (2025). Clinical efficacy of OS-01 peptide formulation in reducing the signs of periorbital skin aging.. International journal of cosmetic science, 47(3), 455-465. https://doi.org/10.1111/ics.13042
MLA
Zonari, Alessandra, et al. "Clinical efficacy of OS-01 peptide formulation in reducing the signs of periorbital skin aging.." International journal of cosmetic science, 2025. https://doi.org/10.1111/ics.13042
RethinkPeptides
RethinkPeptides Research Database. "Clinical efficacy of OS-01 peptide formulation in reducing t..." RPEP-14666. Retrieved from https://rethinkpeptides.com/research/zonari-2025-clinical-efficacy-of-os01
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.